Outcomes of Targeted Therapy Plus Immunotherapy and High-Dose Stereotactic Ablative Body Radiotherapy (SABR) for Metastatic Renal Cell Cancer Patients

SABR波动模型 医学 放射治疗 肾细胞癌 肿瘤科 不利影响 离格 内科学 放射外科 随机波动 波动性(金融) 金融经济学 经济
作者
M. Ma,Xianshu Gao,H.Z. Li,K.W. Yang,Weimin Yu,Zhiwen He,Yun Bai,Jin Chen,Z.S. Wang
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:117 (2): e412-e412
标识
DOI:10.1016/j.ijrobp.2023.06.1558
摘要

Stereotactic ablative body radiotherapy (SABR) is one of the treatment options for metastatic renal cell carcinoma (mRCC) but is limited by a lack of data to evaluate targeted therapy plus immunotherapy concurrently with high-dose SABR to multiple sites. We evaluated the safety and disease control for mRCC patients who concurrently received the above tri-modality treatment.Patients were treated with SABR (40-70 Gy/5-10 fractions) for small lesions or partial-SABR (tumor center boosted with 6-8 Gy/3-5 fractions with 50-60 Gy/20-25 fractions to the whole tumor volume) for bulky tumors or tumors adjacent to critical organs. When SABR/partial-SABR was not feasible, a moderate fractionated radiotherapy plan, usually 60Gy/20 fractions were applied. of Targeted therapy plus immunotherapy (PD-1 inhibitor) was not interrupted during or after radiotherapy (RT). Adverse events (AEs) were evaluated. Disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were calculated. The PFS1 was defined as the first progression since the start of RT. The PFS2 was defined as the second progression after the second RT course, if new metastases occurred after first RT were all re-irradiated, and the systemic therapy was not changed. The Kaplan-Meier method was used for time-to-event endpoints.A total of 51 patients, with a median age of 57 yr, were enrolled. The median follow-up was 12 months. There were 75% of patients with intermediate-risk and 18% with favorable-risk disease. 61% of the patients were oligometastatic. 71% had clear cell renal cancer. There were 241 metastases while 161 (67%) were irradiated. 80% of the lesions received SABRP/partial SABR. 1 patient with 14 lesions irradiated received proton therapy. All the surviving patients are continuing using targeted therapy while 81% patients complete at least 1-year PD-1 therapy. 10 patients (20%) had grade 3 drug-related AEs: pneumonitis (n = 2), elevated alanine transaminase (n = 4), myositis (n = 1), hand-foot syndrome myositis (n = 1), enteritis (n = 1), fatigue (n = 1). There were 1 grade 4 AEs of upper gastrointestinal bleeding. No grade 3-5 RT-related AEs was found. ORR and DCR for irradiated lesion were 51% and 98%. Median OS and PFS2 was not reached. Median PFS1 was 14(6-22) months. Estimated 1- and 2-yr OS, PFS1 and PFS2 were 90% and 90%, 56% and 38%, 74% and 51% respectively. Univariate analysis showed that an PFS1 benefit was found in patients who received radiation before systemic therapy failure (p = 0.038).We investigated the high-dose RT in combination of concurrent targeted and immunotherapy in patients with metastatic RCC. We found that this treatment regimen was well tolerated, with good cancer control. Early use of high-dose RT to multi-lesions may improve PFS. Partial-SABR for bulky lesions close to critical organs could be safely and effectively applied under certain circumstances. These encouraging findings warrant further investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kiki完成签到 ,获得积分10
1秒前
小二郎应助fafamimireredo采纳,获得10
1秒前
2秒前
小胖熊完成签到,获得积分10
2秒前
2秒前
bgt发布了新的文献求助10
3秒前
张灬小胖完成签到,获得积分10
3秒前
Mmm发布了新的文献求助10
3秒前
星辰大海应助hhh采纳,获得10
3秒前
3秒前
3秒前
4秒前
4秒前
4秒前
joni完成签到,获得积分10
4秒前
111完成签到,获得积分10
5秒前
会走路的番茄完成签到,获得积分10
5秒前
汉堡包应助闪闪的梦柏采纳,获得10
5秒前
可爱的函函应助菠菜采纳,获得200
5秒前
6秒前
Jenny_Zhan完成签到,获得积分10
6秒前
7秒前
JoshuaChen发布了新的文献求助10
7秒前
火星上香菇完成签到,获得积分10
8秒前
8秒前
暮歌发布了新的文献求助50
8秒前
9秒前
迷路念真完成签到,获得积分20
9秒前
Jenny_Zhan发布了新的文献求助10
9秒前
可耐的发夹完成签到 ,获得积分10
9秒前
fang发布了新的文献求助10
10秒前
爆米花完成签到,获得积分10
10秒前
ZZZ发布了新的文献求助10
10秒前
NexusExplorer应助bgt采纳,获得30
11秒前
12秒前
喜之郎完成签到,获得积分10
12秒前
自然1111发布了新的文献求助10
12秒前
牛姐发布了新的文献求助20
12秒前
迷路念真发布了新的文献求助10
12秒前
JETSTREAM完成签到,获得积分10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Handbook of Marine Craft Hydrodynamics and Motion Control, 2nd Edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3987078
求助须知:如何正确求助?哪些是违规求助? 3529488
关于积分的说明 11245360
捐赠科研通 3267987
什么是DOI,文献DOI怎么找? 1804013
邀请新用户注册赠送积分活动 881270
科研通“疑难数据库(出版商)”最低求助积分说明 808650